Baseline ART

DRUG2 trials

Sponsors

Frontier Biotechnologies Inc., TaiMed Biologics Inc.

Conditions

HIV -1 InfectionHIV-1-infection

Phase 2

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Frontier Biotechnologies Inc.HIV-1-infection

Start: 2018-12-17End: 2022-12-31Target: 80Updated: 2021-09-29

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

Active, not recruitingNCT07215468

TaiMed Biologics Inc.HIV -1 Infection

Start: 2025-12-16End: 2027-08-01Updated: 2026-05-28